Intel stock spikes after report of possible US government stake
In a turbulent market environment, Maxpro Capital Acquisition Corp. (APLM) stock has recorded a new 52-week low, dipping to $6.0 USD, marking a steep decline from its 52-week high of $63. According to InvestingPro analysis, the stock is currently trading below its Fair Value. This latest price level reflects a significant downturn for the company, which has seen its stock value plummet by an alarming 89.28% over the past year. Investors have been closely monitoring APLM’s performance, as the company grapples with the factors contributing to this decline. While the company maintains a healthy current ratio of 2.25 and holds more cash than debt, InvestingPro data reveals concerning metrics about its cash burn rate and profitability outlook. The 52-week low serves as a critical indicator of current investor sentiment and market conditions surrounding the stock. InvestingPro subscribers have access to 11 additional key insights about APLM’s financial position.
In other recent news, Apollomics Inc. and LaunXP International Co., Ltd. have entered into a significant agreement concerning the cancer drug vebreltinib. This deal grants LaunXP exclusive rights to develop and commercialize the drug in combination with an EGFR inhibitor across several Asian markets, excluding mainland China, Hong Kong, and Macau. Under the terms of the agreement, Apollomics will receive an upfront payment of $10 million, with the potential for additional regulatory and pre-commercial milestone payments up to $50 million, along with royalties on net sales.
Vebreltinib, a c-Met inhibitor, has shown potential in preclinical models for targeting pathways involved in tumor growth and resistance to therapies. Apollomics is currently conducting a Phase 2 multicohort trial in the U.S. and other countries, while its partner Avistone has secured conditional approval for the drug in China for multiple indications. This collaboration is part of Apollomics’s strategy to expand the global reach of vebreltinib, both as a standalone treatment and in combination with other therapies. LaunXP aims to enhance cancer treatment outcomes by delaying resistance to EGFR inhibitors through this partnership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.